Buserelin Injection is an artificially synthesized gonadotropin-releasing hormone (GnRH) agonist. Clinically, it is mainly used to treat hormone-dependent diseases such as prostate cancer, endometriosis, and uterine fibroids. Its mechanism of action is to continuously activate the GnRH receptors in the pituitary gland, initially briefly promoting the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) (the "trigger effect"), and then causing receptor downregulation, thereby significantly inhibiting the synthesis and release of gonadotropins, ultimately reducing the levels of estrogen or testosterone in the body to a state similar to castration, achieving the therapeutic goal. This drug is usually administered subcutaneously or intranasally daily. During use, patients may experience hot flashes, decreased libido, increased risk of osteoporosis, and temporary worsening of the initial condition, so it must be used under the strict monitoring of a doctor. Overall, it is an effective prescription drug that regulates the endocrine system to control the progression of related diseases.
Our product forms
Buserelin COA
 |
||
| Certificate of Analysis | ||
| Compound name | Buserelin | |
| CAS No. | 57982-77-1 | |
| Quantity | 50g | |
| Packaging standard | PE bag+Al foil bag | |
| Manufacturer | Shaanxi BLOOM TECH Co.,Ltd | |
| Lot No. | 20251206035 | |
| MFG | Dec.06th2025 | |
| EXP | Dec.06th2028 | |
| Structure |
|
|
| Item | Enterprise standard | Analysis result |
| Appearance | White or off-white loose lumps or powders | Conformed |
| Water content | ≤5.0% | 0.13% |
| Loss on drying | ≤1.0% | 0.26% |
| Heavy Metals | Pb≤0.5ppm | N.D. |
| As≤0.5ppm | N.D. | |
| Hg≤0.5ppm | N.D. | |
| Cd≤0.5ppm | N.D. | |
| Purity (HPLC) | ≥99.0% | 99.10% |
| Single impurity | <0.8% | 0.18% |
| Total microbial count | ≤750cfu/g | 206 |
| E. Coli | ≤2MPN/g | N.D. |
| Salmonella | N.D. | N.D. |
| Ethanol (by GC) | ≤5000ppm | 560pm |
| Storage | Store in a sealed, dark, and dry place below 2-8°C | |
|
|
||
|
|
||
| Chemical Formula | C60H86N16O13 |
| Exact Mass | 1238.66 |
| Molecular Weight | 1239.45 |
| m/z | 1238.66(100.0%),1239.66(64.9%),1240.66(20.7%),1239.65(5.9%),1240.66(3.6%),1241.67(3.5%),1240.6(2.7%),1241.66(1.7%),1241.66(1.2%) |
| Elemental Analysis | C,58.14;H,6.99;N,18.08;O,16.78 |
Non-immune mechanisms of injection site reactions
Buserelin Injection is a gonadotropin-releasing hormone (GnRH) analogue. The non-immune mechanism of the injection site reaction mainly involves the direct stimulation effect of the drug on the subcutaneous tissue, factors related to the injection operation, and the influence of the chemical and physical properties of the drug. The following will analyze these aspects in detail:
Direct Stimulatory Effect of Drugs on Subcutaneous Tissue
After the administration of the buserelin injection subcutaneously, it may trigger a pro-inflammatory response in the local tissue. This response is not mediated by the immune system but is caused by the direct stimulation of the subcutaneous tissue by the drug. The specific manifestations are:
Stimulating reaction
A pro-inflammatory reaction of the subcutaneous tissue to the injected drug, which can occur immediately. The severity of this reaction is related to the drug dose; the higher the dose, the more intense the reaction may be. The stimulating reaction typically manifests as symptoms such as redness, swelling, pain, and itching at the injection site.
Drug metabolism and local accumulation
During the local metabolism of buserelin, certain metabolites may be produced, which may have a further stimulating effect on the subcutaneous tissue. Additionally, if the drug accumulates excessively locally, it may also increase the burden on the local tissue, triggering or exacerbating the injection site reaction.
Factors related to injection procedures
Improper injection procedures are also an important factor in triggering injection site reactions that are not related to the immune mechanism. Specific aspects include:
Improper injection technique
If the injection angle or depth is inappropriate, it may cause the drug to be injected into the muscle layer or blood vessels, thereby triggering more severe local reactions. Additionally, injecting too quickly may increase the pressure on the local tissues, leading to drug extravasation and local irritation.
Inappropriate injection site selection
Choosing to inject in areas such as those that are painful, bruised, red, hard, scarred, or with stretch marks on the skin may increase the risk of injection site reactions. The skin tissues in these areas may already be damaged or have inflammation, making them more sensitive to the drug's irritation.
Insufficient pre-injection preparation
If the injection site is not thoroughly cleaned and disinfected, it may lead to local infection or contamination, thereby triggering or exacerbating the injection site reaction. Moreover, if the drug is not carefully inspected before injection, such as if there are particles or discoloration in the drug, and it is still used, it may increase the risk of local reaction.
Effects of Drug Chemical and Physical Properties
The chemical and physical properties of the buserelin injection may also have an impact on the injection site reaction. Specifically including:
The pH value of the drug: The pH value of the drug may affect the acid-base balance of the local tissue, thereby triggering or exacerbating local reactions. If the pH value of the drug is significantly different from that of the local tissue, it may cause irritation or damage to the local tissue.
The osmotic pressure of the drug: The osmotic pressure of the drug may also affect the water balance of the local tissue, thereby triggering or exacerbating local reactions. If the osmotic pressure of the drug is too high or too low, it may cause water loss or accumulation in the local tissue, resulting in symptoms such as swelling or pain.
The excipients of the drug: The brezonil injection may contain certain excipients, such as stabilizers, solubilizers, etc. These excipients may have a stimulating effect on the local tissue, thereby triggering or exacerbating the reaction at the injection site.
Busserol injection is an artificially synthesized gonadotropin-releasing hormone (GnRH) analogue. By mimicking the physiological effects of natural GnRH, it binds to the GnRH receptors in the pituitary gland and achieves bidirectional regulation of sex hormone secretion. Its mechanism of action can be divided into the initial stimulation stage and the continuous inhibition stage. This characteristic makes it a core drug for treating hormone-dependent diseases such as prostate cancer, breast cancer, and endometriosis.
Initial stimulation stage: Brief increase in sex hormones
After the first administration of buserelin, it quickly binds to the GnRH receptors in the anterior pituitary gland, mimicking the pulsatile secretion pattern of natural GnRH. This process can cause the blood drug concentration to reach its peak within 15 minutes and trigger a sharp secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The increase in LH and FSH will further stimulate the testes or ovaries, resulting in a brief increase in testosterone (in males) or estradiol (in females).
This stage is referred to as the "flare-up" reaction and is a key feature of the mechanism of action of buserelin. For prostate cancer patients, a temporary increase in testosterone may trigger a temporary proliferation of tumor cells. Therefore, anti-androgen drugs (such as flutamide) need to be combined to block the stimulating effect of androgens on tumor cells. Studies have shown that when buserelin is used alone, the clinical response rate of prostate cancer patients is less than 10%, while when combined with flutamide, the response rate can increase to 60%, significantly improving the treatment effect.
Continuous Suppression Phase: Long-term Decrease in Sex Hormone Levels
After continuous use of buserelin for 1-2 weeks, the pituitary GnRH receptors undergo desensitization due to prolonged exposure to high concentrations of the drug. This process leads to the inhibition of LH and FSH secretion, thereby reducing testosterone and estradiol levels to the castration state. In men, testosterone levels can drop below 50 ng/dL; in women, estradiol levels can drop below 20 pg/mL.
This long-term inhibitory effect is the core mechanism of buserelin in treating hormone-dependent diseases:
Prostate cancer: By reducing testosterone levels, buserelin can inhibit the growth and spread of tumor cells. Clinical studies have shown that patients with prostate cancer treated with buserelin can have a five-year survival rate increased by approximately 30%. Additionally, buserelin can alleviate symptoms such as urinary difficulty, frequent urination, and urgent urination caused by prostate cancer, significantly improving the quality of life of patients.
Breast cancer: For patients with estrogen receptor-positive breast cancer, buserelin reduces the production of estradiol and lowers the stimulation effect of estrogen on cancer cells. For male breast cancer patients, a combination of buserelin and flutamide can achieve partial remission, with a median remission period of 24 months.
Endometriosis: Buserelin reduces the level of estradiol, inhibiting the proliferation and inflammatory response of endometrial tissue, thereby alleviating symptoms such as dysmenorrhea, irregular menstruation, and other symptoms. About 70% of patients experience significant improvement in pain symptoms after treatment, and the recurrence rate is lower than that of the surgical group.
The physiological basis and clinical significance of bidirectional regulation
The bidirectional regulatory effect of buserelin stems from its dynamic influence on the GnRH receptor in the pituitary gland:
Initial stimulus: Simulate the pulsatile secretion of natural GnRH, briefly activating receptor function.
Continuous inhibition: Through the receptor desensitization mechanism, long-term blocking of receptor signal transduction.
This characteristic enables buserelin to be used not only for inhibiting the gonadal axis in patients with precocious puberty, but also for the chemical castration treatment of prostate cancer. For example, in the treatment of central precocious puberty, buserelin can delay the progression of bone age and improve final height; while in the treatment of prostate cancer, its chemical castration effect is comparable to surgical castration, but avoids the psychological impact and irreversibility brought by surgery.
Extended Applications and Precautions of the Mechanism of Action
The mechanism of buserelin is also extended to the treatment of other hormone-dependent diseases, such as uterine fibroids and iatrogenic cortisol hypersecretion:
Uterine fibroids
By reducing estrogen levels, buserelin can shrink the size of fibroids and alleviate symptoms such as excessive menstruation. However, long-term use requires monitoring of bone density to prevent osteoporosis.
Iatrogenic cortisol hypersecretion
Buserelin can alleviate symptoms by inhibiting the secretion of ACTH by the pituitary gland and reducing cortisol synthesis.
When using buserelin, the following points should be noted:
Side effect monitoring
Hot flashes, headaches, mood swings and other menopausal symptoms are common. Long-term use may lead to decreased bone density and increased cardiovascular risks.
Lifestyle adjustments
It is recommended that patients maintain a balanced diet, engage in regular exercise, and take calcium and vitamin D supplements to reduce the risk of adverse reactions.
Regular assessment
Hormone levels and disease progression should be monitored regularly, and the treatment plan should be adjusted promptly.
FAQ
1. What is Buserelin injection used for?
Medical uses
Buserelin is approved for the treatment of hormone-responsive cancers including prostate cancer and premenopausal breast cancer, sex hormone-dependent uterine diseases including endometrial hyperplasia, endometriosis, and uterine fibroids, and in assisted reproduction for female infertility.
2. What diseases does it mainly treat?
It is mainly used to treat diseases such as prostate cancer, endometriosis and uterine fibroids that grow depending on estrogen or androgen.
3. Why might the symptoms worsen during the initial stage of treatment?
At the beginning of medication, there will be a brief stimulation of hormone secretion (i.e., the "ignition effect"), which may cause pain or temporary elevation of indicators. Usually, this will be alleviated after a few weeks as the hormone levels are suppressed.
Hot Tags: buserelin injection, China buserelin injection manufacturers, suppliers, salcatonin injection, intranasal desmopressin acetate, best glp 1 peptide, desmomelt tablets, glp1 shot, etelcalcetide structure
